Celtaxsys spins 'clinically meaningful' data on another failed PhII cystic fibrosis study
At first glance, you would think Atlanta-based Celtaxsys had plenty to be happy about in its release about their Phase II study of an experimental …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
